United States
Australia
Canada
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom
BioCentury This Week
Similar topics: fda and biotech
Chart positions today · Brazil
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like The Readout Loud, try…
Pink Sheet Podcasts
Similar topics: fda and drug
Citeline Podcasts
Also in Business
Conversations in Drug Development
Similar topics: drug and fda
Business Of Biotech
Also in Business
On The Pen GLP-1 News
Also in Business
Ranking history · Brazil
No ranking history for this show in Brazil over the last 7 days.
Latest episodes
-
417: Hospitals' next lucrative bet — longevity clinics
October 16, 2026 · 20 minLongevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on STAT reporter Sarah Todd to…
-
416: NIH funding uncertainty thwarts U.S. researchers
October 8, 2026 · 34 minHow has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie? We discuss all that and more on this week’s episode of “The Readout LOUD,”…
-
415: Mistrust in science and a juicy gene-editing lawsuit
October 1, 2026 · 31 minOn this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of…
-
The FDA's Overton era, and dispatches from Shanghai
September 24, 2026 · 30 min"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague…
-
Definium's new psychedelics data, and a reprieve for international scientists
September 17, 2026 · 28 minInternational researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the…
Show 7 more episodesShow fewer episodes
-
Why two promising heart drugs flopped and what's next
September 10, 2026 · 31 minOn this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development…
-
411: Capricor's data clash and a fugitive in the C-suite
July 30, 2026 · 37 minIs the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more…
-
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
July 23, 2026 · 1 hr 4 minWhat does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that…
-
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
July 16, 2026 · 36 minOn this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced…
-
408: Whistleblower takes on health insurance and FDA commissioner candidates
July 9, 2026 · 44 minWhy does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and…
-
407: The mysterious case of Eli Lilly's obesity drug
June 25, 2026 · 43 minWho got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of…
-
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
June 18, 2026 · 36 minThis week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for…
About the show
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.